Thrombosis Journal最新文献

{"title":"Inhibitory effects of ethanol on pathological high shear stress-induced platelet adhesion and aggregation: a microfluidic chip model study.","authors":"Yu Liu, Cui He, Yemei Shen, Xuanrong Huan, Xuemei Gao, Surong Deng, Yuan Li","doi":"10.1186/s12959-026-00881-6","DOIUrl":"10.1186/s12959-026-00881-6","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the concentration- and shear-dependent effects of ethanol on platelet adhesion, activation, and aggregation under pathologically high shear stress mimicking arterial stenosis, and to determine whether its primary target is platelet function or the coagulation cascade. This study aims to resolve the paradoxical relationship between alcohol consumption and cardiovascular risk.</p><p><strong>Methods: </strong>Using a validated microfluidic chip platform, we established in vitro models simulating normal vasculature (venous shear: 300 s⁻¹; arterial shear: 1500 s⁻¹) and 80% stenotic vessels (pathological shear: 8200 s⁻¹). Whole blood incubated with ethanol (0.125%-1%) was perfused through microchannels, and platelet adhesion/aggregation was quantified via real-time fluorescence microscopy. Platelet activation under pathological shear was assessed by P-selectin (CD62P) expression using flow cytometry. Comprehensive coagulation function was evaluated through plasma recalcification tests, coagulation profiles (PT/APTT/TT), and thromboelastography (TEG).</p><p><strong>Results: </strong>Ethanol inhibited platelet adhesion and aggregation in a concentration-dependent manner across all shear conditions. Notably, this inhibition exhibited significant shear-dependent enhancement, with maximal efficacy observed at pathological high shear (8200 s⁻¹; p < 0.0001 vs. lower shear rates). Ethanol suppressed shear-induced platelet activation, evidenced by reduced P-selectin expression. Crucially, at all tested concentrations, ethanol did not alter plasma recalcification kinetics, PT/APTT/TT parameters, or TEG metrics (R-value, MA-value, CI-value), confirming its selective targeting of platelets without affecting coagulation cascades.</p><p><strong>Conclusion: </strong>Ethanol exerts concentration- and shear-dependent inhibitory effects on platelet adhesion, activation, and aggregation, with peak efficacy under pathological high shear simulating arterial stenosis. This study, for the first time in a clinically relevant microfluidic model, demonstrates that ethanol specifically targets platelet function while sparing coagulation pathways. These findings provide a mechanistic basis for ethanol's paradoxical cardiovascular effects-potentially attenuating thrombotic risk in stenotic regions while increasing bleeding propensity.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13436132/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148057042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thrombosis biomarkers: utility in early diagnosis and prognosis of severe pneumonia.","authors":"Yanru Fan, Rufei Ma, Yuan Zhang, Biao Hu, Huiling Wang, Lan Gao","doi":"10.1186/s12959-026-00876-3","DOIUrl":"10.1186/s12959-026-00876-3","url":null,"abstract":"<p><strong>Background: </strong>Pneumonia is a major health problem and the most important causes of mortality in all age groups worldwide. We investigated new automation technology to detect plasma biomarkers, including thrombinantithrombin complex (TAT), α2-plasmininhibitor-plasmin complex (PIC), soluble thrombomodulin (sTM), and tissue plasminogen activator-inhibitor complex (t-PAI·C), and evaluated their diagnostic performance and prognostic value for severe pneumonia patients.</p><p><strong>Methods: </strong>We collected 414 patients date with pneumonia. sTM, t-PAI·C, TAT, PIC were measured by qualitative chemiluminescence immunoassay performed on HISCL analyzers. Other laboratory tests were evaluated on the day of non-severe pneumonia and severe pneumonia diagnosis.</p><p><strong>Results: </strong>There were significant differences in sTM, t-PAI·C, TAT, PIC (p < 0.0001), WBC (p = 0.023), PCT (p = 0.007) and IL-6 (p = 0.002) between the severe pneumonia and non-severe pneumonia groups, Logistic regression analysis showed that sTM (p = 0.001), t-PAI·C (p = 0.001), TAT (p = 0.022), PIC (p = 0.000) and APTT (p = 0.013) were independent risk factors for severe pneumonia. Logistic regression analysis showed that t-PAI·C (p = 0.006) was an independent risk factor for hospital mortality in severe pneumonia. The AUC of sTM combined with t-PAI·C, TAT and PIC on diagnosis of patients with severe pneumonia was 0.868 (95% CI: 0.837, 0.899). Kaplan-Meier survival analysis with a log-rank test showed the in-hospital death rate of severe pneumonia was higher in the high TAT (≥ 5.58ng/mL) level than in group with low TAT (< 5.58ng/mL) level (log rank < 0.029). The same trend with high t-PAI·C was also found in severe pneumonia patients (log rank < 0.021).</p><p><strong>Conclusions: </strong>The thrombosis markers are helpful for the diagnosis and prognostic assessment of severe pneumonia.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13435470/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148057040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, and systemic immune-inflammation index as predictors of venous thromboembolism in patients with diffuse large B-cell lymphoma.","authors":"Waad Almalki, Atheer Alenezi, Rawan Almutairi, Anfal Alsadhan","doi":"10.1186/s12959-026-00875-4","DOIUrl":"10.1186/s12959-026-00875-4","url":null,"abstract":"<p><strong>Background: </strong>Neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) have been linked to venous thromboembolism (VTE) across various cancer types; however, their relationship with diffuse large B-cell lymphoma (DLBCL) remains largely unexplored. This study aimed to investigate the role of these inflammatory markers in predicting the risk of VTE in patients with DLBCL.</p><p><strong>Method: </strong>A retrospective cohort study was conducted to analyze NLR, PLR, and SII in 224 DLBCL patients prior to chemotherapy. Of them, 31 (13.8%) patients were diagnosed with VTE, while the remaining 193 patients were considered as the control group.</p><p><strong>Results: </strong>The median age was 55 (30) years, with men representing 57% of the patients. The majority of VTE events occurred during active treatment (58%), however; 42% of VTE cases were diagnosed prior to the initiation of treatment. NLR, PLR, and SII were significantly higher in DLBCL patients who developed VTE compared with the control (P = 0.003, P = 0.015, and P = 0.027, respectively). The optimal cut-off values were > 2.41 for NLR (P = 0.003, with a sensitivity of 68% and specificity of 63%), > 185 for PLR (P = 0.016, with a sensitivity of 71% and specificity of 67%), and > 656 for SII (P = 0.027, with a sensitivity of 64% and specificity of 55%). Area under the curve values were 66% for NLR, 63% for PLR, and 62% for SII. The multivariate logistic regression model showed that NLR (ORa 3.750, P = 0.001) and PLR (ORa 5.211, P < 0.001) were independent predictors of VTE in DLBCL patients.</p><p><strong>Conclusions: </strong>NLR and PLR could be beneficial predictors of potential VTE in DLBCL patients without additional costs to the healthcare systems.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13419304/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148057027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A scoping review of factors affecting activated clotting time measurement results.","authors":"Yuki Itagaki, Mineji Hayakawa, Kaori Okamoto, Nozomi Yashima, Takashi Ito","doi":"10.1186/s12959-026-00874-5","DOIUrl":"10.1186/s12959-026-00874-5","url":null,"abstract":"<p><strong>Background: </strong>Activated clotting time (ACT), a widely used point-of-care test, monitors anticoagulation in clinical settings. Despite ACT technology advancements, some uncertainties remain regarding the factors influencing ACT measurements and inter-device variability. Although ACT is widely used for anticoagulation monitoring in clinical practice, the factors affecting ACT values are not fully understood, complicating their interpretation. This scoping review aims to address these challenges by examining the factors affecting ACT measurements, highlighting gaps in current knowledge.</p><p><strong>Methods: </strong>A systematic search was conducted in MEDLINE (PubMed), including animal studies, clinical trials, observational studies, in vitro experiments, and systematic reviews. Article selection involved a two-step process: initial title and abstract screening followed by a full-text review, this was performed by three independent reviewers. Data from the included studies were charted and extracted, collecting information on factors influencing ACT measurements.</p><p><strong>Results: </strong>A total of 1908 records were identified, with 74 studies included after screening. Key factors influencing ACT measurements included platelet count, platelet inhibitors, and hematocrit levels. Direct thrombin inhibitors, low-molecular-weight heparin, and direct oral anticoagulants prolonged ACT with characteristics different from heparin. Aprotinin and nafamostat mesylate interacted with coagulation activators during ACT measurements affecting results. Significant differences in ACT measurements were observed between devices.</p><p><strong>Conclusions: </strong>This scoping review comprehensively analyzed factors influencing ACT and emphasized ACT measurement variability across devices. Despite its widespread use as a point-of-care test for anticoagulation monitoring, ACT's limitations and device discrepancies highlight the need for cautious interpretation in clinical settings.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13366791/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147983119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pooled estimate of anticoagulation control with warfarin therapy among adult patients in Ethiopia: a systematic review and meta-analysis.","authors":"Firafan Shuma Teka, Ayana Korsa, Bekan Gudata Gindaba, Gemechu Gelana Ararame, Jebesa Desisa Hordofa, Lalesa Tadesse Chuko, Nega Abebe Meshesha, Birbirsa Sefera Senbeta","doi":"10.1186/s12959-026-00865-6","DOIUrl":"10.1186/s12959-026-00865-6","url":null,"abstract":"<p><p>BACKGROUND: Warfarin is widely used to prevent thromboembolic events; however, achieving optimal anticoagulation control remains challenging. In Africa, Time in Therapeutic Range (TTR) is generally low, and no nationally representative pooled estimate exists for Ethiopia. OBJECTIVE: To estimate adequate anticoagulation control (TTR ≥ 65%) among adult patients receiving warfarin therapy in Ethiopia. METHODS: A systematic review and meta-analysis was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and registered in PROSPERO (CRD420251271413). Databases including PubMed/MEDLINE, Scopus, Embase, Web of Science, African Journals Online, and Google Scholar were searched from inception to December 10, 2025. Observational studies conducted in Ethiopia among adult warfarin users reporting TTR were included, while studies lacking relevant outcomes or involving non-adult populations were excluded. Study quality was assessed using the Joanna Briggs Institute tool. A random-effects model was applied to estimate pooled anticoagulation control, and heterogeneity was evaluated using the I² statistic. RESULTS: Six studies comprising a total of 2,022 participants were included in this systematic review and meta-analysis. All studies were retrospective cross-sectional and conducted among adult patients receiving warfarin therapy in hospital settings across Ethiopia. The pooled estimate of adequate anticoagulation control (TTR ≥ 65%) was 34.30% (95% CI: 28.16–40.44), with substantial heterogeneity (I² = 79.09%). The mean TTR ranged from 29% to 47.24% across the included studies. Subgroup analysis showed relatively higher anticoagulation control in Addis Ababa (39.29%) compared to other regions (Amhara and Oromia) (22.19%). CONCLUSION: Anticoagulation control among Ethiopian patients on warfarin is suboptimal. Strengthening anticoagulation management services and establishing dedicated clinics are recommended. </p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":"24 1","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13182117/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147975729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the relationship between thrombus burden, inflammation indices, and prognosis in central and peripheral pulmonary embolism.","authors":"Bengü Kaan, Şeyma Başlılar, Ayşe Çapar, Cemre Abacı, Yahya Baraç","doi":"10.1186/s12959-026-00873-6","DOIUrl":"10.1186/s12959-026-00873-6","url":null,"abstract":"<p><strong>Objective: </strong>Early risk stratification is critical to clinical management of acute pulmonary embolism (APE). We aimed to evaluate the relationships among thrombus localization, thrombus burden, and inflammatory indices in patients with APE, and to assess the prognostic value of these parameters.</p><p><strong>Materials and methods: </strong>This retrospective, single-center study included adult patients with computed tomography pulmonary angiography (CTPA)-confirmed APE. Patients with active infection, hematologic or active solid organ malignancy, or immunosuppressive therapy were excluded. The cohort comprised 821 patients. Thrombus localization was assessed by CTPA and classified as central or peripheral. Thrombus burden was quantified using the Qanadli score. The Systemic Immune-Inflammation Index (SII), Systemic Inflammatory Response Index (SIRI), and Aggregate Index of Systemic Inflammation (AISI) were calculated from hematologic parameters at admission. Clinical, laboratory, and echocardiographic data were analyzed to assess 28-day mortality.</p><p><strong>Results: </strong>In patients with central thrombus location, the Qanadli score, right heart overload findings, pulmonary artery pressure, troponin, and B-type natriuretic peptide (pro-BNP) levels were significantly higher (p < 0.05). However, no significant relationship was found between thrombus localization and 28-day mortality, and the Qanadli score was also not associated with mortality (p > 0.05). SII, SIRI, and AISI values were significantly higher among patients who died (p < 0.05). In multivariate analyses, age, pro-BNP, C-reactive protein (CRP), red cell distribution width (RDW), and SII were identified as independent predictors of mortality (p < 0.05). In the receiver operating characteristics (ROC) analysis, SII showed the highest discriminatory power for predicting mortality (AUC = 0.748; p < 0.001).</p><p><strong>Conclusion: </strong>In APE, although thrombus burden and localization may correlate with clinical severity, mortality appears to be primarily driven by systemic inflammation. SII can serve as a practical, complementary biomarker for early risk stratification.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13339269/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147932930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the content and quality of deep vein thrombosis on Bilibili, TikTok, and YouTube: a cross-sectional study.","authors":"Ming Wang, Shaobo Wang, Min-Yi Yin","doi":"10.1186/s12959-026-00834-z","DOIUrl":"10.1186/s12959-026-00834-z","url":null,"abstract":"<p><strong>Background: </strong>Deep vein thrombosis (DVT) is a form of venous thromboembolism, occurring in approximately 1.6 out of every 1000 people annually. Social media platforms have become influential tools for disseminating health information.This study aimed to comprehensively evaluate the content, quality, and reliability of DVT-related videos on TikTok, Bilibili, and YouTube.</p><p><strong>Methods: </strong>A comprehensive search was conducted on Bilibili, TikTok (Douyin), and YouTube using three keywords - \"\", \"Deep vein thrombosis\", and \"DVT\" - across all platforms.Two reviewers independently assessed video characteristics, categorized content (definition, etiologies and causations, symptoms, treatment, prevention, and complications), and evaluated quality using validated tools [Global Quality Scale(GQS), The Journal of the American Medical Association (JAMA), and modified DISCERN (mDISCERN) scores].</p><p><strong>Results: </strong>Analyzing 300 DVT-related videos revealed distinct content distribution patterns across platforms. On TikTok, prevention (24%), etiologies and causations (23%), and symptoms (21%) predominated; on Bilibili, treatment (30%), prevention (29%), and complications (16%) were most common; while on YouTube, treatment (25%), symptoms (24%), and etiologies and causations (18%) were prioritized. Quality assessment showed moderate overall scores: median GQS of 4 (Q1-Q3: 3-4) for TikTok and YouTube, compared to 3 (Q1-Q3: 3-4) for Bilibili (p = 0.02).TikTok videos had significantly higher modified DISCERN scores (4, Q1-Q3: 3-4) compared to Bilibili (3, Q1-Q3: 3-4) and YouTube (3, Q1-Q3: 2-3) (p < 0.0001). TikTok and Bilibili videos had higher JAMA scores (2, Q1-Q3: 2-2) than YouTube (2, Q1-Q3: 1-2) (p < 0.0001).</p><p><strong>Conclusions: </strong>Although DVT-related videos on social media offer valuable information on prevention and treatment, content on diagnosis and epidemiology is lacking.Videos created by medical professionals showed higher quality across all assessment metrics.Efforts should focus on improving the comprehensiveness and reliability of health information on social media platforms to enhance public awareness of DVT.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13339561/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147875770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence and risk factors of deep vein thrombosis in critically ill patients: a systematic review and meta-analysis.","authors":"Tian Zuo, Jiajun Yu, Xin Yin, Hanliang Wu, Shuai Mao","doi":"10.1186/s12959-026-00870-9","DOIUrl":"10.1186/s12959-026-00870-9","url":null,"abstract":"<p><strong>Background: </strong>Deep vein thrombosis (DVT) is a frequent and often silent complication in intensive care unit (ICU) patients, markedly increasing the risk of pulmonary embolism and death. However, comprehensive quantitative evidence on ICU-DVT incidence and associated risk factors remains scarce.</p><p><strong>Objective: </strong>To synthesize global data on the epidemiology of ICU-DVT and identify independent risk factors, providing a basis for evidence-based, risk-stratified prevention.</p><p><strong>Methods: </strong>We systematically searched PubMed, Embase, Cochrane Library, and Web of Science to July 2024 for observational studies reporting ICU-DVT incidence and risk factors. Pooled odds ratios (ORs) were calculated using random-effects models (PROSPERO ID: CRD42024583844).</p><p><strong>Results: </strong>A total of 186 studies were included, involving 203,880 ICU patients. The overall incidence of DVT was 10.4% (95% CI 8.9%-12.0%). The incidence was significantly higher in COVID-19 patients than in non-COVID-19 patients (12.4% vs. 8.4%, p < 0.01). Medical ICUs had the highest incidence (16.3%), followed by trauma ICUs (11.6%), general ICUs (10.1%), neuro ICUs (8.6%), and surgical ICUs (7.9%). The incidence varied by region (Asia 12.5%, Europe 11.8%; America 9.3%, Oceania 9.1%). Systematic screening significantly improved DVT detection rates compared with clinically suspected diagnosis (14.6% vs. 7.9%). Meta-analysis revealed that central venous catheterization, a history of DVT, use of vasoactive agents, mechanical ventilation, prolonged ICU stay, and malignancy were associated with increased DVT odds.</p><p><strong>Conclusions: </strong>ICU-DVT affects approximately 1 in 10 patients and is associated with distinct modifiable and non-modifiable risk factors. The influence of diagnostic strategies on DVT incidence underscores the necessity for standardized screening in the ICU. Future prospective, large-scale studies are warranted to validate causal relationships and enable the development of risk prediction tools for precision prevention.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13335205/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147875801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physical activity patterns in people with haemophilia with and without arthropathy: a cross-sectional study using wearable sensors.","authors":"Yuya Mawarikado, Midori Shima, Naoki Matsumoto, Asuka Sakata, Ryohei Kawasaki, Kohei Tatsumi, Tetsuhiro Soeda, Suguru Harada, Naoto Seriu, Yusuke Inagaki, Akira Kido, Keiji Nogami","doi":"10.1186/s12959-026-00869-2","DOIUrl":"10.1186/s12959-026-00869-2","url":null,"abstract":"<p><strong>Background: </strong>In haemophilia, recurrent joint bleeding often results in joint destruction, which in turn leads to reduced physical activity (PA) and decreased quality of life (QOL). While maintaining high PA levels is important in the care of people with haemophilia (PwH), it remains unclear whether PwH without joint disease can maintain adequate activity levels.</p><p><strong>Aim: </strong>This descriptive cross-sectional study sought to compare moderate-to-vigorous physical activity (MVPA) levels among 19 PwH with haemophilic arthropathy (HA), 12 PwH without HA, and 15 non-PwH.</p><p><strong>Methods: </strong>A total of 46 males wore a triaxial accelerometer (wGT3X-BT, ActiGraph) during daily activities for seven consecutive days. A bout of MVPA was defined as at least 10 consecutive minutes of moderate-intensity or higher activity. MVPA was expressed as the percentage of the total wear time spent in MVPA, and the total number of MVPA bouts was also recorded.</p><p><strong>Results: </strong>Both PwH groups demonstrated significantly lower MVPA percentages and fewer MVPA bouts than the controls (p < 0.01). No MVPA bouts were recorded among 52.6% of PwH with HA versus 25% of PwH without HA. No significant differences were observed in sedentary or light activity between the PwH groups.</p><p><strong>Conclusions: </strong>PA levels were significantly reduced in PwH, regardless of joint status, suggesting that factors beyond joint damage, such as fear of bleeding or behavioural avoidance, may play a role. These findings highlight the need for individualized, evidence-based interventions to safely promote physical activity and improve long-term health outcomes in PwH.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13321524/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147843187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transition to Emicizumab from standard-dose FVIII prophylaxis in young children with hemophilia A: a real-world study.","authors":"Juan Ye, Kun Huang","doi":"10.1186/s12959-026-00868-3","DOIUrl":"10.1186/s12959-026-00868-3","url":null,"abstract":"<p><strong>Background: </strong>Real-world evidence on transition from standard-dose FVIII to Emicizumab prophylaxis in young children with hemophilia A remains limited, particularly in developing countries.</p><p><strong>Methods: </strong>We performed a single-center, retrospective, self-controlled study in boys with severe hemophilia A without inhibitors. Outcomes during 12 months of standard-dose factor VIII (FVIII) prophylaxis were compared with outcomes during 12 months after transition to Emicizumab prophylaxis (in this real-world cohort, most patients received reduced-dose maintenance regimens). Annualized bleeding rates (overall, treated, joint, and spontaneous) and zero-bleeding proportions were assessed. Direct annual prophylaxis drug costs were calculated using locally applicable drug prices and converted to USD.</p><p><strong>Results: </strong>Thirty-one boys were included with a median age of 4.5 years. During FVIII prophylaxis, the median FVIII dose was 32.3 IU/kg/infusion with a median 3.1 infusions/week; median trough FVIII was 3.9 IU/dL. After transition, mean Emicizumab exposure was 4.2 mg/kg/month (range 3.0-6.0) with a mean dosing interval of 14 days. Overall ABR decreased from 2.48 to 0.32, treated ABR from 1.64 to 0.29, joint ABR from 0.83 to 0.13, and spontaneous ABR from 0.26 to 0 (all P < 0.05). The proportion of patients with zero bleeds increased from 35% to 81% (P < 0.001), and zero treated bleeds from 52% to 69% (P < 0.05). Mean annual prophylaxis drug costs were lower with Emicizumab than with FVIII (34,417 vs. 47,168 USD; P < 0.001).</p><p><strong>Conclusions: </strong>In this selected pediatric cohort of children who transitioned from standard-dose FVIII to Emicizumab and remained on treatment for at least 12 months, lower observed bleeding rates and lower direct prophylaxis drug costs were seen during the Emicizumab period. These findings should be interpreted descriptively because the retrospective design and eligibility criteria introduced substantial selection bias.</p><p><strong>Trial registration: </strong>Not applicable.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13285309/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147843199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}